Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Biotechnology stories

Nov 16, 2026

Sofinnova Partners raises €725M crossover fund for late-stage European biotechs

Paris-based Sofinnova Partners secured €725 million ($815 million) for its second crossover fund targeting late-stage European biopharma companies, addressing a financing gap in the sector.

Nov 16, 2026·3 sources
00
Nov 13, 2026

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Swiss immune drug developer Windward Bio raised $175 million in its IPO, the biotech sector's 30th listing of the year, to advance lung disease drugs licensed from China.

Nov 13, 2026·2 sources
00
Nov 10, 2026

AstraZeneca acquires vaccine biotech Omniose to bolster pipeline

AstraZeneca acquired early-stage US biotech Omniose, which is developing vaccines against serious bacterial infections, integrating it into its infectious diseases division.

Nov 10, 2026·2 sources
00
Nov 7, 2026

T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease

UK-based T-Therapeutics closed a $133 million Series B funding round led by Advent Life Sciences and British Business Bank to advance T-cell therapies targeting cancer and autoimmune diseases.

Nov 7, 2026·2 sources
00
Nov 2, 2026

Fresenius signs biosimilars development agreement with WuXi Biologics

German healthcare company Fresenius has entered a partnership with China's WuXi Biologics to develop a pipeline of biosimilar drugs, expanding its presence in the biologics market.

Nov 2, 2026·3 sources
00
Oct 30, 2026

FDA approves Inovio's Voceryq for recurrent respiratory papillomatosis

The U.S. Food and Drug Administration has approved Inovio Pharmaceuticals' treatment Voceryq for recurrent respiratory papillomatosis, a rare throat disease. The approval sent Inovio's shares surging.

Oct 30, 2026·4 sources
00
Oct 29, 2026

Flagship Pioneering merges Etiome, Cellarity and Empress Therapeutics into Etcelera

Biotechnology startup creator Flagship Pioneering is combining three of its portfolio companies—Etiome, Cellarity, and Empress Therapeutics—into a new venture called Etcelera. The merged company will use artificial intelligence and drug discovery tools to predict which experimental medicines might succeed in clinical trials.

Oct 29, 2026·2 sources
00
Oct 28, 2026

US bans imports from BGI Genomics, MGI Tech and affiliate over Xinjiang forced labor allegations

The United States banned imports from three Chinese genomics companies—BGI Genomics, MGI Tech, and Shenzhen BGI Tech—adding them to the Uyghur Forced Labor Prevention Act Entity List over allegations they enabled forced labor of Uyghurs and other ethnic minorities in China's Xinjiang region. The companies have rejected the allegations.

Oct 28, 2026·8 sources
00
Oct 23, 2026

Star Therapeutics raises $200 million to advance pipeline after spinout successes

Star Therapeutics has secured $200 million in private financing to advance its preclinical programs into clinical trials and expand its pipeline. The funding follows the company's successful track record of spinning out companies including Vega and Electra, with Incyte acquiring one of its spinouts in July 2026.

Oct 23, 2026·5 sources
00
Oct 22, 2026

Trump administration proposes restrictions on US investment in Chinese biotech sector

The Treasury Department issued proposed rules that would severely restrict future US investment in Chinese biotechnology companies, potentially complicating financial ties as American drugmakers increasingly turn to China for clinical trials and manufacturing.

Oct 22, 2026·5 sources
00
Oct 19, 2026

Peter Mac scientists develop CRISPR method to target gene fusions in one in five cancers

Scientists at Peter MacCallum Cancer Centre have developed a new CRISPR approach using PspCas13b nuclease to precisely target abnormal gene fusions, which occur in approximately 20% of cancers. The technique targets the unique molecular fingerprint created when two genes fuse together, potentially offering a new personalized treatment strategy.

Oct 19, 2026·1 source
00
Oct 8, 2026

Endeavor BioMedicines' taladegib meets primary endpoint in phase 2b trial for idiopathic pulmonary fibrosis

Endeavor BioMedicines announced that its WHISTLE-PF phase 2b trial of taladegib met its primary endpoint, demonstrating statistically significant improvement in lung function (ppFVC) compared to placebo in patients with IPF. The company claims the drug has potential to reverse disease course, unlike current therapies that only slow progression.

Oct 8, 2026·2 sources
00

Argenx reports positive Phase 2 results for FB102 in celiac disease, plans Phase 3 trial

Argenx announced its experimental drug FB102 met the primary endpoint in a Phase 2 study for celiac disease, providing first evidence that blocking CD122 can prevent gluten-induced intestinal damage. The company plans to advance the drug into Phase 3 development, though the news was overshadowed by a simultaneous setback in Sjögren's disease that sent shares falling.

Oct 8, 2026·3 sources
00
Oct 5, 2026

Epicrispr reports updated trial data for epigenetic editing treatment in FSHD muscular dystrophy

Epicrispr Biotechnologies presented encouraging updated findings from testing of its epigenetic editing treatment for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disease. The data builds the case for the company's therapeutic approach to treating the condition.

Oct 5, 2026·2 sources
00
Sep 28, 2026

Adicet Bio's off-the-shelf CAR-T therapy shows promise in lupus trial

Adicet Bio reported positive early trial results for prula-cel, an off-the-shelf gamma delta CAR-T therapy for systemic lupus erythematosus. At 12 months, 54% of evaluable patients achieved DORIS remission with no severe side effects, surpassing benchmarks set by personalized CAR-T treatments.

Sep 28, 2026·4 sources
00

Kodiak Sciences' Zenkuda and KSI-501 meet primary endpoints in wet AMD phase 3 trial

Kodiak Sciences announced that both investigational therapies, Zenkuda (tarcocimab tedromer) and KSI-501, met their primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration, matching the performance of Regeneron's Eylea at one year. The company's stock surged over 65% in premarket trading following the announcement.

Sep 28, 2026·4 sources
00
Sep 24, 2026

Kyverna Therapeutics reports one-year durability data for autoimmune cell therapy

Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.

Sep 24, 2026·4 sources
00
Sep 17, 2026

FDA approves Ultragenyx's Fayuvi, first gene therapy for Sanfilippo syndrome type A

The FDA granted full approval to Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, marking the first-ever approved treatment for the ultra-rare, fatal neurodegenerative disease. The approval comes after a previous regulatory rejection and represents a significant milestone for patients with this devastating condition.

Sep 17, 2026·4 sources
00
Sep 3, 2026

AbbVie's etentamig succeeds in Phase 3 trial for multiple myeloma

AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.

Sep 3, 2026·3 sources
00
Aug 24, 2026

Bristol Myers ends blood cancer drug partnership with Cellares

Bristol Myers Squibb terminated its partnership with cell therapy startup Cellares to expand manufacturing of its personalized blood cancer therapy, prompting Cellares to lay off 100 employees.

Aug 24, 2026·2 sources
00
Aug 12, 2026

Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies

Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.

Aug 12, 2026·4 sources
00
Aug 11, 2026

Skylark Bio doses first patient in gene therapy trial for GJB2-related deafness

Skylark Bio has dosed the first patient in its SONIX Phase 1/2 trial of SKY-GJB2, a gene therapy targeting GJB2-related hearing loss, the most common genetic cause of pediatric deafness. The trial follows earlier breakthrough gene therapy treatments that restored hearing in children born deaf.

Aug 11, 2026·3 sources
00
Aug 10, 2026

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32 Billion in Rare Epilepsy Deal

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.

Aug 10, 2026·6 sources
00

AbCellera's experimental menopause drug shows significant reduction in hot flashes in Phase 2 trial, shares surge 40%

AbCellera Biologics reported that its non-hormonal menopause treatment ABCL-635 significantly reduced the frequency and severity of hot flashes in a 92-person Phase 2 trial, with the drug meeting both primary endpoints after four weeks. The results sent the company's shares surging nearly 40% in early trading.

Aug 10, 2026·9 sources
00

Silence Therapeutics reports positive Phase 2 trial results for divesiran in rare blood cancer

Silence Therapeutics announced that its Phase 2 SANRECO trial of divesiran met its primary endpoint in patients with polycythemia vera, a rare blood cancer, with data showing the treatment stabilized red blood cell levels and reduced phlebotomies to 0.2 per patient over 36 weeks. The company's stock rallied significantly on the news.

Aug 10, 2026·9 sources
00

Top claims

  • ▪Sofinnova Crossover II has already deployed capital into clinical-stage biotechnology companies CellCentric and Hemab Therapeutics
  • ▪Sofinnova Partners partner Kinam Hong led an initial investment in immune drugmaker Abivax, which later reached a public market valuation of approximately $7 billion
  • ▪Sofinnova Partners partner Kinam Hong stated that Europe faces a scale-up financing problem rather than an innovation problem for life sciences companies

People involved

Michael SenaXi JinpingDonald TrumpJoe Biden

Subtopics

Drug Policy, Pricing & Approval11Clinical trials9Drug Approval and Clinical Trials9Pharmaceutical Industry8Rare diseases7Biotech startup5Drug development5Autoimmune disease4Immunotherapy4Venture capital funding4Autoimmune disease treatments3Biotech innovation3Cancer & Oncology3Clinical evaluation3Clinical Trial Design & Evaluation3FDA drug approval3Mergers & acquisitions (M&A)3Mergers and acquisitions3Pharma3Respiratory diseases3Biologic therapies2CAR T-cell therapy2Corporate strategy2Drug discovery2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories